for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Virbac SA

VIRB.PA

Latest Trade

384.00EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

188.20

 - 

397.50

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
384.00
Open
--
Volume
--
3M AVG Volume
0.13
Today's High
--
Today's Low
--
52 Week High
397.50
52 Week Low
188.20
Shares Out (MIL)
8.44
Market Cap (MIL)
3,247.87
Forward P/E
32.18
Dividend (Yield %)
0.20

Next Event

Full Year 2021 Virbac SA Earnings Release

Latest Developments

More

Virbac H1 Revenue Up At Eur 529.4 Mln

Virbac Buys 15% Of Shares Of Centrovet For $17.7 Million

Virbac Announces FDA Approval Of New Cancer Treatment For Dogs

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Virbac SA

Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.

Industry

Biotechnology & Drugs

Contact Info

13eme rue LID, Bp 27, Carros Cedex

06510

France

+33.4.92087100

https://corporate.virbac.com/

Executive Leadership

Marie-Helene Dick-madelpuech

Chairwoman of the Board of Directors

Sebastien Huron

Chief Executive Officer, Member of the Group Executive Committee

Habib Ramdani

Deputy Chief Executive Officer, Chief Financial Officer, Member of the Group Executive Committee

Marc Bistuer

Deputy Chief Executive Officer - Qualified Person , Head of Global Industrial Operations & Corporate Quality Assurance, Member of the Group Executive Committee

Pierre Madelpuech

Vice Chairman of the Board of Directors

Key Stats

2.11 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

0.9K

2019

0.9K

2020

0.9K

2021(E)

1.0K
EPS (EUR)

2018

3.630

2019

7.260

2020

8.770

2021(E)

11.933
Price To Earnings (TTM)
19.88
Price To Sales (TTM)
3.30
Price To Book (MRQ)
4.63
Price To Cash Flow (TTM)
15.48
Total Debt To Equity (MRQ)
18.16
LT Debt To Equity (MRQ)
6.53
Return on Investment (TTM)
18.81
Return on Equity (TTM)
13.15

Latest News

Latest News

BRIEF-Virbac To Assign US Rights Of SENTINEL® Trademarks To MSD Sante Animale

* READY TO ASSIGN US RIGHTS TO THE SENTINEL® TRADEMARKS TO MSD SANTE ANIMALE

BRIEF-Vir and Alnylam Identify RNAi Therapeutic Development Candidate for the Treatment of COVID-19

* VIR AND ALNYLAM IDENTIFY RNAI THERAPEUTIC DEVELOPMENT CANDIDATE, VIR-2703 (ALN-COV), TARGETING SARS-COV-2 FOR THE TREATMENT OF COVID-19

BRIEF-Virbac Q1 Revenue Up At 247.7 Million Euros

* 2020 Q1 REVENUE ROSE BY +14.3% AT COMPARABLE EXCHANGE RATES,

BRIEF-Pebble Labs And Virbac Sign Comprehensive Commercial Agreement

* PEBBLE LABS SAYS PEBBLE LABS AND VIRBAC ANNOUNCE SIGNING OF COMPREHENSIVE COMMERCIAL AGREEMENT FOR AQUACULTURE DISEASE PREVENTION Source text for Eikon: Further company coverage: (Gdansk Newsroom)

Virbac 2018 operating profit grows helped by U.S. market

French veterinary pharmaceutical company Virbac said 2018 operating profit before depreciation of assets arising from acquisitions grew by 9.6 percent, helped by a strong performance in the U.S. and all other countries except Chile.

France's Virbac sees higher margin as U.S profitability improves

French veterinary pharmaceutical company Virbac said on Monday it was raising its full year operating margin forecast as a result of improved profitability in the United States and growth in emerging markets and Europe.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up